|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
We retrospectively identified 31 lung ADCs diagnosed with <i>BRAF</i> V600E mutation by standard molecular sequencing methods and reviewed their clinical characteristics and pathological features.
|
31234388 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
This implies limiting the number of tissue slides despite the existence of specific and sensitive biomarkers (ALK, ROS1, BRAF V600E, PD-L1) and the obligation to distinguish lung adenocarcinoma (TTF-1 positive) from squamous cell carcinoma (p40 positive).
|
30268486 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
CLINVAR |
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity.
|
26619011 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
Further, the optimal therapeutic strategy to block non-V600E BRAF-mutant LA remains unclear.
|
27834212 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
Activating BRAF(V600E) (Val600Glu) mutations are found in about 1-2% of lung adenocarcinomas, which might provide an opportunity for targeted treatment in these patients.
|
27080216 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
The advent of effective targeted therapy for BRAF(V600E) -mutant lung adenocarcinomas necessitates further exploration of the unique clinical features and behavior of advanced-stage BRAF-mutant lung adenocarcinomas.
|
25273224 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
Approximately 2% of lung adenocarcinomas have BRAF (v-Raf murine sarcoma viral oncogene homolog B) mutations, including V600E and other types.
|
26200454 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
Lung adenocarcinomas showed significantly higher non-p.V600E mutations (86%) than did colorectal cancers (23%) and melanomas (34%).
|
26386083 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
Among the 204 lung ADCs tested, 11 cases (5.4%) carried HER2 exon 20 insertions and 4 cases (2.0%) had BRAF V600E mutation.
|
26102513 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
The activating BRAF mutation p.V600E has been identified in many cancers, including colon and lung adenocarcinomas, papillary thyroid cancer, malignant melanoma, and hairy cell leukemia (HCL).
|
25583765 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.
|
24888229 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
This study compared the specificity and sensitivity of IHC with other methods for the detection of BRAF(V600E) in primary lung adenocarcinoma.
|
23131393 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
IHC using the VE1 clone and FLEX linker is a specific method for the detection BRAF V600E and may be an alternative to molecular biology for the detection of mutations in lung adenocarcinomas.
|
23927882 |
2013 |
|
Adenocarcinoma of lung (disorder)
|
|
0.800 |
GeneticVariation
|
BEFREE |
The histopathology of BRAF-V600E-mutated lung adenocarcinoma.
|
18636014 |
2008 |